First Citizens Bank & Trust’s Nektar Therapeutics NKTR Stock Holding History

First Citizens Bank & Trust’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-779	Closed	-$10.9K	–	456
2024 Q1	$10.9K	Sell	779 -1,084	-58%	-$11.3K	﹤0.01%	429
2023 Q4	$15.8K	Sell	1,863 -1,558	-46%	-$11.8K	﹤0.01%	357
2023 Q3	$30.6K	Sell	3,421 -3,121	-48%	-$30K	﹤0.01%	346
2023 Q2	$56.4K	Buy	+6,542	New	+$69.8K	﹤0.01%	347
2022 Q1	–	Sell	-994	Closed	-$202K	–	461
2021 Q4	$202K	Buy	994 +5	+0.5%	+$1.08K	0.01%	418
2021 Q3	$266K	Buy	989 +68	+7%	+$16.4K	0.01%	327
2021 Q2	$237K	Sell	921 -219	-19%	-$60.6K	0.01%	356
2021 Q1	$342K	Buy	1,140 +333	+41%	+$104K	0.02%	261
2020 Q4	$206K	Buy	+807	New	+$209K	0.01%	354
2018 Q2	–	Sell	-137	Closed	-$219K	–	445
2018 Q1	$219K	Buy	+137	New	+$177K	0.03%	383

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Citizens Bank & Trust's NKTR Position: Q2 2024 in Review

First Citizens Bank & Trust sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 779 shares — an estimated $10.9K sold.

First Citizens Bank & Trust first reported a position in NKTR in Q1 2018 and held it in 10 quarters. The position peaked at $342K in Q1 2021. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

First Citizens Bank & Trust reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
First Citizens Bank & Trust sold 779 Nektar Therapeutics shares in Q2 2024, an estimated $10.9K.
First Citizens Bank & Trust first reported a position in Nektar Therapeutics in Q1 2018 and held it in 10 quarters.
First Citizens Bank & Trust's Nektar Therapeutics position peaked at $342K in Q1 2021.
133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on First Citizens Bank & Trust's 13F filing for Q2 2024, filed 19 Jul 2024.